Mark D. Novara - 15 May 2025 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role: EVP & CHIEF COMMERCIAL OFFICER
Signature: /s/ Rachel Malina, Attorney-in-Fact for Mark D. Novara
Issuer symbol: TNDM
Transactions as of: 15 May 2025
Net transactions value: +$14,226
Form type: 4
Filing time: 19 May 2025, 18:06:58 UTC
Previous filing: 19 Mar 2025
Next filing: 05 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	12400 HIGH BLUFF DRIVE, SAN DIEGO	/s/ Rachel Malina, Attorney-in-Fact for Mark D. Novara	19 May 2025	0002000342

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNDM	Common Stock	Award	$16,791	+870	+3.6%	$19.30	25,004	15 May 2025	Direct	F1
transaction	TNDM	Common Stock	Options Exercise	$0	+304	+1.2%	$0.000000	25,308	15 May 2025	Direct
transaction	TNDM	Common Stock	Tax liability	$2,565	-113	-0.45%	$22.70	25,195	15 May 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNDM	Restricted Stock Unit	Options Exercise	$0	-304	-33%	$0.000000	609	15 May 2025	Common Stock	304		Direct	F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).
F2	Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
F3	Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F4	Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F5	RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.